Access Program Information
<p>The purpose of this study is to provide treatment with <strong>Nivolumab</strong> in combination with <strong>Ipilimumab</strong> and to assess the safety and tolerability of this combination in subjects who are <strong>anti-cytotoxic T lymphocyte associated antigen (CTLA)-4 treatment-naive</strong> and have <strong>unresectable or metastatic melanoma</strong>.</p>